{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:22:06Z","timestamp":1787664126173,"version":"build-2736575974"},"reference-count":157,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"18","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,20]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>The Baveno Cooperation is a consortium of internationally renowned experts committed to setting standards for the clinical management of patients with advanced chronic liver disease, with a particular emphasis on complications related to portal hypertension. Updated every five years and endorsed by major scientific societies, the Baveno recommendations have significantly influenced clinical practice and improved patient outcomes worldwide. The latest Baveno consensus, Baveno VII, provided a series of recommendations that have shifted our understanding of chronic liver disease and portal hypertension and profoundly shaped clinical practice. However, many areas of research remain to be explored in the short to intermediate term to enable a more personalized medicine approach. This review highlights some of the most relevant advancements introduced in Baveno VII and discusses future challenges.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003785","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T16:00:17Z","timestamp":1755532817000},"page":"2268-2282","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Future research direction of portal hypertension based on Baveno VII"],"prefix":"10.1097","volume":"138","author":[{"given":"Xuefeng","family":"Luo","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangchuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Hernandez-Gea","sequence":"additional","affiliation":[{"name":"Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Cl\u00ednic, Cl\u00ednic Barcelona, ERN-RareLiver (Health Care Provider of the European Reference Network on Rare Liver Disorders), CSUR Centro de referencia del Sistema Nacional de Salud en Enfermedad Hep\u00e1tica Vascular Compleja en adultos, Barcelona, Spain"},{"name":"FRCB-IDIBAPS (Fundaci\u00f3 de Recerca Cl\u00ednic Barcelona-Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer), Barcelona, Spain; CIBEREHD (Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Hep\u00e1ticas y Digestivas), Madrid, Spain; AGAUR SGR2021 01115 Catalonia, Spain"},{"name":"Medicine Department, Faculty of Medicine, and Health Science, Universitat de Barcelona, Barcelona, Catalonia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"R1-20250920","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies","volume":"44","author":"D\u2019Amico","year":"2006","journal-title":"J Hepatol"},{"key":"R2-20250920","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1002\/hep.28824","article-title":"Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The \u201cAnticipate\u201d study","volume":"64","author":"Abraldes","year":"2016","journal-title":"Hepatology"},{"key":"R3-20250920","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1016\/j.cgh.2021.10.023","article-title":"Decompensation in advanced nonalcoholic fatty liver disease may occur at lower hepatic venous pressure gradient levels than in patients with viral disease","volume":"20","author":"Bassegoda","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R4-20250920","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/s-0040-1708806","article-title":"Noninvasive diagnostics for portal hypertension: A comprehensive review","volume":"40","author":"Mandorfer","year":"2020","journal-title":"Semin Liver Dis"},{"key":"R5-20250920","doi-asserted-by":"crossref","first-page":"723","DOI":"10.14309\/ajg.0000000000000994","article-title":"Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease","volume":"116","author":"Pons","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"R6-20250920","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/j.cgh.2022.09.032","article-title":"The sequential application of Baveno VII criteria and VITRO score improves diagnosis of clinically significant portal hypertension","volume":"21","author":"Jachs","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R7-20250920","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S2468-1253(24)00234-6","article-title":"Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: A modelling study","volume":"9","author":"Jachs","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R8-20250920","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2024.09.014","article-title":"Exploring algorithms to select candidates for non-selective beta-blockers in cirrhosis: A post hoc analysis of the PREDESCI trial","volume":"82","author":"Dajti","year":"2025","journal-title":"J Hepatol"},{"key":"R9-20250920","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/HEP.0000000000000342","article-title":"Quantifying the benefit of nonselective beta-blockers in the prevention of hepatic decompensation: A Bayesian reanalysis of the PREDESCI trial","volume":"78","author":"Rowe","year":"2023","journal-title":"Hepatology"},{"key":"R10-20250920","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J Hepatol"},{"key":"R11-20250920","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jhep.2022.05.021","article-title":"Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis","volume":"77","author":"Villanueva","year":"2022","journal-title":"J Hepatol"},{"key":"R12-20250920","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/apt.17824","article-title":"Improving primary prophylaxis of variceal bleeding by adapting therapy to the clinical stage of cirrhosis. A competing-risk meta-analysis of individual participant data","volume":"59","author":"Villanueva","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"R13-20250920","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1097\/HEP.0000000000000647","article-title":"AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis","volume":"79","author":"Kaplan","year":"2024","journal-title":"Hepatology"},{"key":"R14-20250920","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - Renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"R15-20250920","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/HEP.0000000000000652","article-title":"Further decompensation in cirrhosis. Results of a large multicenter cohort study supporting Baveno VII statements","volume":"79","author":"D\u2019Amico","year":"2024","journal-title":"Hepatology"},{"key":"R16-20250920","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1111\/liv.15937","article-title":"Influence of further decompensation on survival across clinical stages of decompensated cirrhosis: The role of portal hypertension and HVPG changes","volume":"44","author":"Garcia-Guix","year":"2024","journal-title":"Liver Int"},{"key":"R17-20250920","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2021.04.022","article-title":"Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis","volume":"75","author":"Villanueva","year":"2021","journal-title":"J Hepatol"},{"key":"R18-20250920","doi-asserted-by":"crossref","first-page":"101231","DOI":"10.1016\/j.jhepr.2024.101231","article-title":"Progressive systemic inflammation precedes decompensation in compensated cirrhosis","volume":"7","author":"S\u00e1nchez-Aldehuelo","year":"2025","journal-title":"JHEP Rep"},{"key":"R19-20250920","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2020.06.013","article-title":"The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology","volume":"73","author":"Trebicka","year":"2020","journal-title":"J Hepatol"},{"key":"R20-20250920","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jhep.2022.09.005","article-title":"Severity of systemic inflammation is the main predictor of ACLF and bleeding in individuals with acutely decompensated cirrhosis","volume":"78","author":"Zanetto","year":"2023","journal-title":"J Hepatol"},{"key":"R21-20250920","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1136\/gutjnl-2020-322712","article-title":"Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes","volume":"70","author":"Jachs","year":"2021","journal-title":"Gut"},{"key":"R22-20250920","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jhep.2015.10.018","article-title":"Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure","volume":"64","author":"Mookerjee","year":"2016","journal-title":"J Hepatol"},{"key":"R23-20250920","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3350\/cmh.2022.0104","article-title":"Management of Refractory Ascites","volume":"29","author":"Wong","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"R24-20250920","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s12072-023-10536-7","article-title":"Asia-Pacific association for study of liver guidelines on management of ascites in liver disease","volume":"17","author":"Singh","year":"2023","journal-title":"Hepatol Int"},{"key":"R25-20250920","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1177\/0300060517735231","article-title":"Current management of refractory ascites in patients with cirrhosis","volume":"46","author":"Zhao","year":"2018","journal-title":"J Int Med Res"},{"key":"R26-20250920","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41395-018-0185-6","article-title":"Refractory Ascites in Liver Cirrhosis","volume":"114","author":"Adebayo","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"R27-20250920","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0168-8278(97)80427-8","article-title":"Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo","volume":"26","author":"Fern\u00e1ndez-Esparrach","year":"1997","journal-title":"J Hepatol"},{"key":"R28-20250920","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/0016-5085(88)90691-9","article-title":"Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis","volume":"94","author":"Gin\u00e8s","year":"1988","journal-title":"Gastroenterology"},{"key":"R29-20250920","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1053\/j.gastro.2016.09.016","article-title":"Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites","volume":"152","author":"Bureau","year":"2017","journal-title":"Gastroenterology"},{"key":"R30-20250920","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"R31-20250920","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jhep.2009.05.031","article-title":"Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension","volume":"51","author":"Manolakopoulos","year":"2009","journal-title":"J Hepatol"},{"key":"R32-20250920","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/hep.21492","article-title":"Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study","volume":"45","author":"Bruno","year":"2007","journal-title":"Hepatology"},{"key":"R33-20250920","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7326\/0003-4819-147-10-200711200-00003","article-title":"Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis","volume":"147","author":"Veldt","year":"2007","journal-title":"Ann Intern Med"},{"key":"R34-20250920","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2009.12.028","article-title":"Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis","volume":"52","author":"Cardoso","year":"2010","journal-title":"J Hepatol"},{"key":"R35-20250920","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.14309\/ajg.0000000000001158","article-title":"Decompensation in direct-acting antiviral cured hepatitis c virus compensated patients with clinically significant portal hypertension: Too rare to warrant universal beta-blocker therapy","volume":"116","author":"Tosetti","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"R36-20250920","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/j.gastro.2017.07.016","article-title":"Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis","volume":"153","author":"Lens","year":"2017","journal-title":"Gastroenterology"},{"key":"R37-20250920","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J Hepatol"},{"key":"R38-20250920","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jhep.2020.05.050","article-title":"Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension","volume":"73","author":"Lens","year":"2020","journal-title":"J Hepatol"},{"key":"R39-20250920","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jhep.2021.09.013","article-title":"Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR","volume":"76","author":"D\u2019Ambrosio","year":"2022","journal-title":"J Hepatol"},{"key":"R40-20250920","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1053\/j.gastro.2018.10.033","article-title":"What Are the benefits of a sustained virologic response to direct-acting antiviral therapy for hepatitis C virus infection?","volume":"156","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"key":"R41-20250920","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jhep.2022.08.025","article-title":"Non-invasive tests for clinically significant portal hypertension after HCV cure","volume":"77","author":"Semmler","year":"2022","journal-title":"J Hepatol"},{"key":"R42-20250920","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jhep.2024.04.007","article-title":"EASL position paper on clinical follow-up after HCV cure","volume":"81","author":"Reiberger","year":"2024","journal-title":"J Hepatol"},{"key":"R43-20250920","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"R44-20250920","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"R45-20250920","doi-asserted-by":"crossref","first-page":"e758","DOI":"10.1002\/osp4.758","article-title":"The effects of weight loss interventions on children and adolescents with non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"10","author":"Sohouli","year":"2024","journal-title":"Obes Sci Pract"},{"key":"R46-20250920","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/liv.15614","article-title":"Sleeve gastrectomy causes weight-loss independent improvements in hepatic steatosis","volume":"43","author":"McGlone","year":"2023","journal-title":"Liver Int"},{"key":"R47-20250920","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/hepr.13989","article-title":"Effects of weight loss on metabolic dysfunction-associated fatty liver disease in Japanese people: Non-alcoholic fatty liver disease in the Gifu area, longitudinal analysis study","volume":"54","author":"Hasegawa","year":"2024","journal-title":"Hepatol Res"},{"key":"R48-20250920","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/apt.17888","article-title":"Meta-analysis: Prevalence and impact of alcohol abstinence in alcohol-associated cirrhosis","volume":"59","author":"Lim","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"R49-20250920","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1016\/j.cgh.2022.11.033","article-title":"Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis","volume":"21","author":"Hofer","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R50-20250920","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"key":"R51-20250920","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis","volume":"150","author":"Abraldes","year":"2016","journal-title":"Gastroenterology"},{"key":"R52-20250920","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jama.2024.27441","article-title":"Simvastatin and rifaximin in decompensated cirrhosis: A randomized clinical trial","volume":"333","author":"Pose","year":"2025","journal-title":"JAMA"},{"key":"R53-20250920","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/apt.15331","article-title":"Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis","volume":"50","author":"Vilar-Gomez","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"R54-20250920","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/MEG.0000000000002754","article-title":"Clinical outcomes with metformin use in diabetic patients with compensated cirrhosis: a systematic review and meta-analysis","volume":"36","author":"Peppas","year":"2024","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R55-20250920","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","article-title":"Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis","volume":"143","author":"Villa","year":"2012","journal-title":"Gastroenterology"},{"key":"R56-20250920","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/liv.13115","article-title":"Diabetes mellitus in patients with cirrhosis: clinical implications and management","volume":"36","author":"Elkrief","year":"2016","journal-title":"Liver Int"},{"key":"R57-20250920","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.3390\/jcm12062253","article-title":"The effects of sglt2 inhibitors on liver cirrhosis patients with refractory ascites: A literature review","volume":"12","author":"Miyamoto","year":"2023","journal-title":"J Clin Med"},{"key":"R58-20250920","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/cld.714","article-title":"SGLT2 inhibitors and cirrhosis: A unique perspective on the comanagement of diabetes mellitus and ascites","volume":"11","author":"Saffo","year":"2018","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"R59-20250920","doi-asserted-by":"crossref","first-page":"618","DOI":"10.14309\/ajg.0000000000000995","article-title":"Empagliflozin eliminates refractory ascites and hepatic hydrothorax in a patient with primary biliary cirrhosis","volume":"116","author":"Kalambokis","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"R60-20250920","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1002\/hep.31270","article-title":"Sodium-glucose cotransporter 2 inhibitors ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes","volume":"72","author":"Montalvo-Gordon","year":"2020","journal-title":"Hepatology"},{"key":"R61-20250920","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejim.2024.08.012","article-title":"Empagliflozin controls cirrhotic refractory ascites along with improvement of natriuresis and circulatory, cardiac, and renal function: A pilot study","volume":"130","author":"Kalambokis","year":"2024","journal-title":"Eur J Intern Med"},{"key":"R62-20250920","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1111\/bcp.16139","article-title":"A potential novel treatment for cirrhosis-related ascites: Empagliflozin is safe and tolerable in advanced chronic liver disease","volume":"90","author":"Shen","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"R63-20250920","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1136\/gutjnl-2015-309262","article-title":"U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients","volume":"64","author":"Tripathi","year":"2015","journal-title":"Gut"},{"key":"R64-20250920","first-page":"895","article-title":"Validation of prognostic scores for clinical outcomes in cirrhotic patients with acute variceal bleeding","volume":"15","author":"Motola-Kuba","year":"2016","journal-title":"Ann Hepatol"},{"key":"R65-20250920","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/hep.27006","article-title":"Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage","volume":"60","author":"Seo","year":"2014","journal-title":"Hepatology"},{"key":"R66-20250920","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.cgh.2014.11.019","article-title":"Risk of bacterial infection in patients with cirrhosis and acute variceal hemorrhage, based on child-pugh class, and effects of antibiotics","volume":"13","author":"Tandon","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R67-20250920","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/poh2.35","article-title":"Antibiotic prophylaxis in cirrhosis patients with upper gastrointestinal bleeding: An updated systematic review and meta-analysis","volume":"1","author":"Wong","year":"2022","journal-title":"Portal Hypertens Cirrhosis"},{"key":"R68-20250920","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jhep.2021.04.029","article-title":"Current knowledge and management of portal vein thrombosis in cirrhosis","volume":"75","author":"Senzolo","year":"2021","journal-title":"J Hepatol"},{"key":"R69-20250920","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1111\/liv.14936","article-title":"Fresh frozen plasma transfusion in acute variceal haemorrhage: Results from a multicentre cohort study","volume":"41","author":"Mohanty","year":"2021","journal-title":"Liver Int"},{"key":"R70-20250920","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/hep.20593","article-title":"Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial","volume":"41","author":"Shaheen","year":"2005","journal-title":"Hepatology"},{"key":"R71-20250920","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/hep.30304","article-title":"Proton pump inhibitors are associated with minimal and overt hepatic encephalopathy and increased mortality in patients with cirrhosis","volume":"70","author":"Nardelli","year":"2019","journal-title":"Hepatology"},{"key":"R72-20250920","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2016.09.007","article-title":"Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population study","volume":"152","author":"Tsai","year":"2017","journal-title":"Gastroenterology"},{"key":"R73-20250920","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/apt.12875","article-title":"Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: A propensity score matched cohort study","volume":"40","author":"Min","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R74-20250920","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jhep.2021.03.026","article-title":"Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis","volume":"75","author":"Mart\u00ednez","year":"2021","journal-title":"J Hepatol"},{"key":"R75-20250920","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12876-019-0940-1","article-title":"Endoscopic injection sclerotherapy versus N-Butyl-2 Cyanoacrylate injection in the management of actively bleeding esophageal varices: A randomized controlled trial","volume":"19","author":"Elsebaey","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"R76-20250920","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/hep.28360","article-title":"Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: A multicenter randomized, controlled trial","volume":"63","author":"Escorsell","year":"2016","journal-title":"Hepatology"},{"key":"R77-20250920","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jhep.2020.06.010","article-title":"Determinants of mortality in patients with cirrhosis and uncontrolled variceal bleeding","volume":"74","author":"Kumar","year":"2021","journal-title":"J Hepatol"},{"key":"R78-20250920","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/hep.31913","article-title":"Combination of model for end-stage liver disease and lactate predicts death in patients treated with salvage transjugular intrahepatic portosystemic shunt for refractory variceal bleeding","volume":"74","author":"Walter","year":"2021","journal-title":"Hepatology"},{"key":"R79-20250920","doi-asserted-by":"crossref","first-page":"E50","DOI":"10.1111\/tri.12090","article-title":"Salvage transjugular intrahepatic portosystemic shunt followed by early transplantation in patients with Child C14-15 cirrhosis and refractory variceal bleeding: A strategy improving survival","volume":"26","author":"Rudler","year":"2013","journal-title":"Transpl Int"},{"key":"R80-20250920","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1056\/NEJMoa0910102","article-title":"Early use of TIPS in patients with cirrhosis and variceal bleeding","volume":"362","author":"Garcia-Pagan","year":"2010","journal-title":"N Engl J Med"},{"key":"R81-20250920","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/HEP.0000000000000613","article-title":"Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysis","volume":"79","author":"Nicoara-Farcau","year":"2024","journal-title":"Hepatology"},{"key":"R82-20250920","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/liv.15559","article-title":"Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension","volume":"43","author":"Turco","year":"2023","journal-title":"Liver Int"},{"key":"R83-20250920","first-page":"287","article-title":"Carvedilol for prevention of variceal bleeding: a systematic review and meta-analysis","volume":"32","author":"Malandris","year":"2019","journal-title":"Ann Gastroenterol"},{"key":"R84-20250920","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.cgh.2022.06.007","article-title":"Carvedilol achieves higher hemodynamic response and lower rebleeding rates than propranolol in secondary prophylaxis","volume":"21","author":"Jachs","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R85-20250920","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1053\/j.gastro.2015.05.011","article-title":"Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy","volume":"149","author":"Sauerbruch","year":"2015","journal-title":"Gastroenterology"},{"key":"R86-20250920","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/hep.28318","article-title":"Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + beta-blocker for prevention of variceal rebleeding","volume":"63","author":"Holster","year":"2016","journal-title":"Hepatology"},{"key":"R87-20250920","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hep.28906","article-title":"Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases","volume":"65","author":"Garcia-Tsao","year":"2017","journal-title":"Hepatology"},{"key":"R88-20250920","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/hep.1840160607","article-title":"Prevalence, classification and natural history of gastric varices: A long-term follow-up study in 568 portal hypertension patients","volume":"16","author":"Sarin","year":"1992","journal-title":"Hepatology"},{"key":"R89-20250920","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/liv.15181","article-title":"Update on the management of gastric varices","volume":"42","author":"Luo","year":"2022","journal-title":"Liver Int"},{"key":"R90-20250920","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/liv.15630","article-title":"EUS-guided coil and glue injection versus endoscopic glue injection for gastric varices: International multicentre propensity-matched analysis","volume":"43","author":"Samanta","year":"2023","journal-title":"Liver Int"},{"key":"R91-20250920","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.gie.2024.01.044","article-title":"EUS-guided thrombin injection and coil implantation for gastric varices: feasibility, safety, and outcomes","volume":"100","author":"O\u2019Rourke","year":"2024","journal-title":"Gastrointest Endosc"},{"key":"R92-20250920","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/HEP.0000000000000530","article-title":"AASLD Practice Guidance on the use of TIPS, variceal embolization, and retrograde transvenous obliteration in the management of variceal hemorrhage","volume":"79","author":"Lee","year":"2024","journal-title":"Hepatology"},{"key":"R93-20250920","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S2468-1253(22)00087-5","article-title":"Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial","volume":"7","author":"Lv","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R94-20250920","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/hep.32453","article-title":"Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial","volume":"76","author":"Lv","year":"2022","journal-title":"Hepatology"},{"key":"R95-20250920","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S2468-1253(23)00209-1","article-title":"Diagnosis and management of ectopic varices in portal hypertension","volume":"8","author":"Tranah","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R96-20250920","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.trecan.2020.08.005","article-title":"Cirrhosis: A questioned risk factor for hepatocellular carcinoma","volume":"7","author":"Garrido","year":"2021","journal-title":"Trends Cancer"},{"key":"R97-20250920","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: Results from the Global Burden of Disease Study 2015","volume":"3","author":"Akinyemiju","year":"2017","journal-title":"JAMA Oncol"},{"key":"R98-20250920","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1007\/s10620-007-9750-3","article-title":"Causes of death in patients with unresectable hepatocellular carcinoma","volume":"52","author":"Couto","year":"2007","journal-title":"Dig Dis Sci"},{"key":"R99-20250920","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jhep.2005.01.021","article-title":"MELD score and hepatocellular carcinoma identify patients at different risk of short-term mortality among cirrhotics bleeding from esophageal varices","volume":"42","author":"Amitrano","year":"2005","journal-title":"J Hepatol"},{"key":"R100-20250920","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1053\/jhep.2003.50385","article-title":"Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators","volume":"38","author":"D\u2019Amico","year":"2003","journal-title":"Hepatology"},{"key":"R101-20250920","doi-asserted-by":"crossref","first-page":"500","DOI":"10.5009\/gnl19155","article-title":"Treatment outcomes and prognostic factors of acute variceal bleeding in patients with hepatocellular carcinoma","volume":"14","author":"Lee","year":"2020","journal-title":"Gut Liver"},{"issue":"6","key":"R102-20250920","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"R103-20250920","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/liv.14977","article-title":"Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses","volume":"41","author":"Allaire","year":"2021","journal-title":"Liver Int"},{"key":"R104-20250920","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1148\/radiol.15141252","article-title":"Advanced cirrhosis combined with portal vein thrombosis: A randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding","volume":"276","author":"Luo","year":"2015","journal-title":"Radiology"},{"key":"R105-20250920","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1136\/gutjnl-2017-314634","article-title":"Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: A randomised controlled trial","volume":"67","author":"Lv","year":"2018","journal-title":"Gut"},{"key":"R106-20250920","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ueg2.12089","article-title":"Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failure","volume":"9","author":"Balcar","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"R107-20250920","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.dld.2022.12.014","article-title":"The Baveno VII concept of cirrhosis recompensation","volume":"55","author":"Reiberger","year":"2023","journal-title":"Dig Liver Dis"},{"key":"R108-20250920","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/ajg.2014.145","article-title":"Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis","volume":"109","author":"Kim","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"R109-20250920","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jhep.2009.11.007","article-title":"Efficacy of entecavir in treatment-na\u00efve patients with hepatitis B virus-related decompensated cirrhosis","volume":"52","author":"Shim","year":"2010","journal-title":"J Hepatol"},{"key":"R110-20250920","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jhep.2012.02.033","article-title":"Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy","volume":"57","author":"Peng","year":"2012","journal-title":"J Hepatol"},{"key":"R111-20250920","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.27723","article-title":"Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis","volume":"61","author":"Jang","year":"2015","journal-title":"Hepatology"},{"key":"R112-20250920","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/hep.24361","article-title":"Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"R113-20250920","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/jhep.2001.26512","article-title":"Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort","volume":"34","author":"Yao","year":"2001","journal-title":"Hepatology"},{"key":"R114-20250920","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1399-0012.2005.00340.x","article-title":"Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive\/HBeAg-negative chronic hepatitis B","volume":"19","author":"Nikolaidis","year":"2005","journal-title":"Clin Transplant"},{"key":"R115-20250920","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jhep.2022.07.037","article-title":"Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis","volume":"77","author":"Wang","year":"2022","journal-title":"J Hepatol"},{"key":"R116-20250920","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/apt.16658","article-title":"Determinants of re-compensation in patients with hepatitis B virus-related decompensated cirrhosis starting antiviral therapy","volume":"55","author":"Kim","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"R117-20250920","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jhep.2020.03.031","article-title":"DAA therapy and long-term hepatic function in advanced\/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort","volume":"73","author":"Verna","year":"2020","journal-title":"J Hepatol"},{"key":"R118-20250920","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: Final update of the series(\u2606)","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"R119-20250920","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N Engl J Med"},{"key":"R120-20250920","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"R121-20250920","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","article-title":"Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: A multicentre, open-label, randomised, phase 2 trial","volume":"16","author":"Manns","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R122-20250920","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J Hepatol"},{"key":"R123-20250920","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1053\/j.gastro.2018.03.022","article-title":"Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection","volume":"154","author":"El-Sherif","year":"2018","journal-title":"Gastroenterology"},{"key":"R124-20250920","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12072-018-9914-6","article-title":"Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort)","volume":"13","author":"Gentile","year":"2019","journal-title":"Hepatol Int"},{"key":"R125-20250920","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jhep.2016.11.011","article-title":"Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease","volume":"66","author":"Lackner","year":"2017","journal-title":"J Hepatol"},{"key":"R126-20250920","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/tri.13008","article-title":"Characteristics of liver transplant candidates delisted following recompensation and predictors of such delisting in alcohol-related liver disease: a case-control study","volume":"30","author":"Aravinthan","year":"2017","journal-title":"Transpl Int"},{"key":"R127-20250920","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2021.02.033","article-title":"A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement","volume":"75","author":"Pose","year":"2021","journal-title":"J Hepatol"},{"key":"R128-20250920","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1111\/liv.15676","article-title":"Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis","volume":"43","author":"Hofer","year":"2023","journal-title":"Liver Int"},{"key":"R129-20250920","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","article-title":"Global epidemiology of cirrhosis - aetiology, trends and predictions","volume":"20","author":"Huang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R130-20250920","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"R131-20250920","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/hep.32204","article-title":"Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis","volume":"75","author":"Sanyal","year":"2022","journal-title":"Hepatology"},{"key":"R132-20250920","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41575-023-00846-4","article-title":"Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease","volume":"21","author":"Feng","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R133-20250920","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/HEP.0000000000000456","article-title":"Current challenges and future perspectives in treating patients with NAFLD-related cirrhosis","volume":"80","author":"Mallet","year":"2024","journal-title":"Hepatology"},{"key":"R134-20250920","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S2468-1253(24)00124-9","article-title":"Resmetirom for MASH-related cirrhosis","volume":"9","author":"Feng","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R135-20250920","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"R136-20250920","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/liv.15930","article-title":"The first MASH drug therapy on the horizon: Current perspectives of resmetirom","volume":"44","author":"Petta","year":"2024","journal-title":"Liver Int"},{"key":"R137-20250920","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/apt.16808","article-title":"Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis","volume":"55","author":"Ng","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"R138-20250920","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: A randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R139-20250920","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"\u03b2 blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): A randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"key":"R140-20250920","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jhep.2012.12.011","article-title":"Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis","volume":"58","author":"Reiberger","year":"2013","journal-title":"J Hepatol"},{"key":"R141-20250920","doi-asserted-by":"crossref","first-page":"101170","DOI":"10.1016\/j.jhepr.2024.101170","article-title":"Persistent varices in cured patients: Understanding the role of hepatic venous pressure gradient","volume":"6","author":"Olivas","year":"2024","journal-title":"JHEP Rep"},{"key":"R142-20250920","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/hep.29557","article-title":"Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C","volume":"67","author":"Mauro","year":"2018","journal-title":"Hepatology"},{"key":"R143-20250920","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ueg2.12496","article-title":"Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort","volume":"12","author":"Kondili","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"R144-20250920","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2036.2009.04182.x","article-title":"Systematic review: portal vein thrombosis in cirrhosis","volume":"31","author":"Tsochatzis","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"R145-20250920","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1055\/s-0038-1676981","article-title":"Incidence and recurrence of portal vein thrombosis in cirrhotic patients","volume":"119","author":"Violi","year":"2019","journal-title":"Thromb Haemost"},{"key":"R146-20250920","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.trre.2014.01.003","article-title":"Portal vein thrombosis and liver transplantation: implications for waiting list period, surgical approach, early and late follow-up","volume":"28","author":"Ponziani","year":"2014","journal-title":"Transplant Rev"},{"key":"R147-20250920","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1111\/liv.15009","article-title":"Risk of non-tumoural portal vein thrombosis in patients with HCV-induced cirrhosis after sustained virological response","volume":"41","author":"Mandorfer","year":"2021","journal-title":"Liver Int"},{"key":"R148-20250920","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/j.gastro.2022.06.057","article-title":"Hepatocellular carcinoma risk declines but remains high enough for screening in the first 7 years after hepatitis C virus cure with direct-acting antivirals in patients with cirrhosis or high fibrosis-4 score","volume":"163","author":"Kim","year":"2022","journal-title":"Gastroenterology"},{"issue":"5 Pt 1","key":"R149-20250920","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies","volume":"158","author":"Morgan","year":"2013","journal-title":"Ann Intern Med"},{"key":"R150-20250920","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/hep.32341","article-title":"HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis","volume":"76","author":"Lockart","year":"2022","journal-title":"Hepatology"},{"key":"R151-20250920","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2019.03.027","article-title":"Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients","volume":"71","author":"Cabibbo","year":"2019","journal-title":"J Hepatol"},{"key":"R152-20250920","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/gutjnl-2020-323663","article-title":"Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis","volume":"71","author":"Sapena","year":"2022","journal-title":"Gut"},{"key":"R153-20250920","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jhep.2010.02.026","article-title":"Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease","volume":"53","author":"Eun","year":"2010","journal-title":"J Hepatol"},{"key":"R154-20250920","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1136\/gut.2010.221846","article-title":"Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: Results of the nationwide HEPNET. Greece cohort study","volume":"60","author":"Papatheodoridis","year":"2011","journal-title":"Gut"},{"key":"R155-20250920","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents","volume":"155","author":"Calvaruso","year":"2018","journal-title":"Gastroenterology"},{"key":"R156-20250920","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1053\/j.gastro.2018.07.015","article-title":"Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs","volume":"155","author":"Nahon","year":"2018","journal-title":"Gastroenterology"},{"key":"R157-20250920","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.14309\/ajg.0000000000001399","article-title":"Impact of alcohol abstinence on the risk of hepatocellular carcinoma in patients with alcohol-related liver cirrhosis","volume":"116","author":"Rodr\u00edguez","year":"2021","journal-title":"Am J Gastroenterol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003785","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T04:01:04Z","timestamp":1758340864000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":157,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003785","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]},"assertion":[{"value":"2024-11-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}